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Tubulointerstitial fibrosis is a major feature of chronic kidney disease. Unilateral ureteral obstruction (UUO) in rodents leads to
the development of renal tubulointerstitial fibrosis consistent with histopathological changes observed in advanced chronic kidney
disease in humans.The purpose of this study was to assess the effect of inhibiting angiotensin II receptors or Ras activation on early
renal fibrotic changes induced by UUO. Animals either received angiotensin II or underwent UUO. UUO animals received either
losartan, atorvastatin, and farnesyl transferase inhibitor (FTI) L-744,832, or chaetomellic acid A (ChA). Levels of activated Ras,
phospho-ERK1/2, phospho-Akt, fibronectin, and 𝛼-smooth muscle actin were subsequently quantified in renal tissue by ELISA,
Western blot, and/or immunohistochemistry. Our results demonstrate that administration of angiotensin II induces activation
of the small GTPase Ras/Erk/Akt signaling system, suggesting an involvement of angiotensin II in the early obstruction-induced
activation of renal Ras. Furthermore, upstream inhibition of Ras signalling by blocking either angiotensin AT1 type receptor or by
inhibiting Ras prenylation (atorvastatin, FTI o ChA) reduced the activation of the Ras/Erk/Akt signaling system and decreased the
early fibrotic response in the obstructed kidney. This study points out that pharmacological inhibition of Ras activation may hold
promise as a future strategy in the prevention of renal fibrosis.
1. Introduction
Renal interstitial fibrosis is a common histopathological end-
point in all forms of progressive renal diseases independently
of their etiology. Unilateral ureteral obstruction (UUO) is a
well-established experimental model inmice leading to tubu-
lointerstitial fibrosis in the ligated kidney [1, 2]. Increased
synthesis of angiotensin II (Ang II) has been implicated as
playing a causative role in progression of kidney damage in
obstructive nephropathy [3–5]. Ang II is directly profibrotic
but also acts as a proinflammatory cytokine in the kidney
through the activation of the nuclear factor-𝜅B family of
transcription factors, which in turn, induces an autocrine
response enhancing both Ang II and tumor necrosis factor
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alpha production [6]. By promoting tubulointerstitial infil-
tration of inflammatory cells, Ang II also contributes to the
onset and progression of renal damage in UUO [6]. However,
studies examining the effect of directly targeting Ang II
in UUO-induced renal damage have yielded contradictory
results. Thus, whereas it has been reported that Ang II recep-
tor blockade or angiotensin-converting enzyme inhibition
abrogates fibrosis deposition and myofibroblast proliferation
in some studies of obstructive nephropathy [7–9], in other
studies these interventions have been shown to aggravate
renal damage after UUO [10–12]. These differences may be
due to whether obstruction was partial or complete but they
also suggest that optimal strategies may be better targeted
downstreamof theAng II receptor complex, focused on those
pathways that are implicated in the proinflammatory and
profibrotic responses to Ang II.
Actions of Ang II are mediated via the Ang II type I
(AT1) and type II G-protein coupled receptors (GPCR), as
well as the receptor tyrosine kinases (RTK)s [13, 14]. Specific
profibrotic actions of Ang II are implicated in the appearance
of alpha-smooth muscle actin (𝛼-SMA)-positive fibroblasts
or myofibroblasts and fibronectin accumulation which are
considered prominent features of fibrosis development in the
obstructed kidney [15, 16].
Ras monomeric GTPases play a major role in the con-
trol of proliferation, differentiation, and cell death, con-
necting activated RTKs and GPCRs to the effector path-
ways Raf/mitogen-activated protein kinase (MAPK)/extra-
cellular signal regulated kinases 1 and 2 (ERK1/2) and
phosphatidylinositol-3 kinase (PI3 K)-Akt [17]. Many growth
factors are known to activate intracellular signaling pathways
that converge on Ras activation, including Ang II which has
been reported to stimulate renal Ras/MAPK pathway in vivo
and in vitro [18, 19]. Thus, Muthalif et al. [18] have demon-
strated that Ang II infusion for 6 days induces hypertension
and renal Ras activation, and both phenomena are reversed
by administration of a farnesyl transferase inhibitor (FTI).
However, the effects of acute Ang II administration on Ras
activation have not been assessed.
Activation of Ras and its effectors ERK1/2 and PI3K/Akt
has been reported as mediators in progressive renal damage
[20, 21]. Activation of Ras signaling pathway occurs after
early UUO [22, 23], demonstrating a contribution of Ras
downstream effectors to renal injurywith amain involvement
of ERK1/2 in apoptotic events and Akt in proliferative and
fibrotic response [23]. There are several Ras isoforms (H-,
N- and K-Ras) with different functional properties in fibrotic
processes and in fibroblast biology [24–26]. Thus, we have
observed that H-Ras knock-out (KO) mice show lower fibro-
sis afterUUO[27], whereas in embryonic fibroblasts obtained
from H-Ras or N-Ras KO mice, fibronectin and collagen
synthesis were higher and proliferation and migration were
lower than in wild type fibroblasts [24, 25]. Moreover, K-
Ras knock-down decreases stimulated proliferation in renal
fibroblasts [28] and inhibits fibrosis in a rat experimental
model [29]. It is known that activation of Ras requires several
posttranslational modifications that include prenylation, the
addition of either the 15-carbon isoprenoid farnesy1 or the 20-
carbon isoprenoid geranylgeranyl to cysteine residue(s) at or
near the C-termini of Ras proteins, allowing their anchorage
to the cell membrane and subsequent activation [30]. Some
evidence exists to demonstrate that inhibition of prenylation
reduces extracellular matrix production by fibroblasts “in
vitro” [31]. Thus, we aimed to interrogate the effects of
decreasing prenylation on early UUO-induced Ras pathway
activation and associated fibrotic responses in themouse kid-
ney.Weusedmultiple strategies to address the question: (1) by
inhibiting the synthesis of farnesyl groups using atorvastatin,
an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase-involved in the synthesis of
isoprenoid groups required for Ras prenylation [32, 33], (2) by
directly inhibiting Ras farnesylation using a farnesyl trans-
ferase inhibitor [34], and (3) by treating with chaetomellic
acidA, which selectively blocksH-Ras farnesylation [35] with
reduced off-target toxicity relative to FTIs [36].
2. Methods
2.1. Animals and Disease Model. C57BL/6J male mice were
kept in a germ-free facility, under controlled environmental
conditions (Unidad de Experimentacio´n Animal, University
of Salamanca, Spain). Mice were reared on standard chow
(Panlab, Barcelona, Spain) and provided with water ad libi-
tum. Surgical techniques to produce UUO were performed
as previously described on animals at 2 months of age [23].
All procedures were approved by the Committee for Animal
Care and Use of the University of Salamanca and complied
with the Guide for the Care and Use of Laboratory Animals
of National Research Council.
2.2. Pharmacological Groups and Drug Administration
Angiotensin (Ang II) Group.A group of mice was treated with
a single intraperitoneal dose of Ang II (0.8mg/kg; Sigma,
Saint Louis, MO, USA; 𝑛 = 3 per time point) or saline vehicle
(NaCl 0.9%; 𝑛 = 3). No surgery was performed in this group
of animals and kidneys were removed either 30minutes, 4, or
12 hours after Ang II administration.
LosartanGroup.Agroup of animals received a daily intraperi-
toneal injection of losartan (40mg/kg; Du Pont,Wilmington,
DE, USA; 𝑛 = 5), whereas the corresponding control group
received the vehicle isotonic saline (NaCl 0.9%; 𝑛 = 3), for 4
days. UUO was carried out on the second day of treatment.
Atorvastatin Group. A group of mice were treated with ator-
vastatin calcium (70mg/kg/day; Pfizer, Madrid, Spain; 𝑛 = 4)
by oral gavage, and the corresponding control mice group
were treated with carboxymethylcellulose vehicle (Sigma,
Saint Louis, MO, USA; 𝑛 = 3), once daily for 6 days. UUO
was performed at the fourth day after initiating the treatment.
Farnesyl Transferase Inhibitor (FTI) Group. A group of mice
received a subcutaneous injection of L-744,832 (40mg/kg;
Biomol Inc, Plymouth Meeting, PA, USA; 𝑛 = 5) while a
control group received the vehicle solution (17mM sodium
citrate, 94mM sodium chloride; pH 5.4; 𝑛 = 3), daily for 6
days. UUO was performed on the fourth day of treatment.
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Chaetomellic Acid A Group. A group of mice received subcu-
taneously injected chaetomellic acid A (3mg/kg/day; Santa
Cruz Biotechnology, CA, USA; 𝑛 = 4) during 6 days, whereas
a control group received the vehicle solution (17mM sodium
citrate, 94mM sodium chloride; pH 5.4; 𝑛 = 4). UUO was
performed on the fourth day of treatment.
2.3. Preparation of Kidney Tissue and Protein Analysis. At
endpoint in each group, kidneys were removed under termi-
nal anaesthesia. Methods used for protein analysis, including
affinity precipitation of Ras-GTP or ELISA Ras activation Kit
(Upstate Biotechnology, MA, USA) and immunodetection of
proteins by Western blot and immunohistochemistry, have
been already described [23, 25, 27]. As we have previously
reported, the amount of loading controls for WB such as
tubulin or GAPDH change after UUO [23], and thus we
have decided to control strictly the amount of protein loaded
instead to performWB for these proteins.
2.4. Statistical Analysis. One-way analysis of variance
(ANOVA) was applied for statistical analysis (NCSS 2000
program, Utah, USA). Bonferroni’s or Kruskal-Wallis
multiple-comparison tests were, respectively, employed for
analysis of data with or without normal distribution. Data
were expressed asmean ± Standard Error of theMean (SEM).
𝑃 < 0.05 or𝑍 > 1.96 were considered statistically significant.
3. Results
3.1. Renal Activation of Ras Signaling Pathway after Short-
Term Ang II Infusion. Renal Ras activation, measured by
ELISA,was higher both at 4 and 12 hours after single doseAng
II administration than in saline-treated control group (Ctrl;
Figure 1).
Western blot analysis also detected an Ang II-induced
increase in renal activation of Ras signaling effectors, ERK1/2
and Akt, as demonstrated by measuring the ratio phosphory-
lated (p)/total protein at 4 hours after Ang II administration
(Figures 1(b) and 1(c), resp.).
3.2. Effect of AT1 Receptor Antagonist on Ras Activation
and Renal Changes after UUO. We aimed to determine the
effect of AT1 receptor antagonist losartan on the activation
of Ras/ERK/Akt signaling pathway and the expression of
fibronectin and 𝛼-SMA in kidneys submitted to 3 days of
UUO. Western blot analyses showed that levels of Ras-
GTP, pERK, pAkt, total Akt, fibronectin, and 𝛼-SMA were
significantly higher in obstructed (O) kidneys than in nonob-
structed (NO) kidneys of vehicle-treated animals (Figures
2(a)–2(f)). The increase observed in total Akt levels in kid-
neys submitted to ureteral obstruction (Figure 2(d)) has been
previously described [23]. After receiving losartan treatment,
no significant differences were found for levels of activated
RAS, fibronectin, and 𝛼-SMA in O kidneys compared with
NO kidneys (Figures 2(a), 2(e) and 2(f), resp.), and a similar
pattern was observed for pERK1/2 and pAkt (Figures 2(b)
and 2(c), resp.). No differences between NO groups of treated
and untreated groups were observed for any of the analyzed
proteins.
3.3. Effect of Ras Activation Inhibitors on ERK1/2 and Akt
Activation and Fibrotic Markers after UUO. Our next objec-
tive was to assess whether inhibition of Ras activation after
UUO could modulate activation of its downstream effectors,
ERK1/2, and Akt, as well as expression of fibronectin and
𝛼-SMA in ligated kidneys. For this purpose we treated
the animals with either the HMG-CoA reductase inhibitor
atorvastatin or the farnesyl transferase inhibitor (FTI) L-
744,832 or chaetomellic acid A.
Western blot analysis revealed that whereas O kidneys
of vehicle-treated mice showed higher levels of Ras-GTP,
pERK1/2, pAkt, and total Akt proteins than NO kidneys,
the differences between O and NO kidneys for Ras-GTP,
pERK1/2, pAkt, and total Akt abundance were not significant
(Figures 5(a)–5(d)) in atorvastatin-treated animals (Figures
5(a)–5(d)). Similar results were obtained for fibronectin and
𝛼-SMA, with lower amounts for both proteins detected in the
O kidneys of animals treated with atorvastatin than in O kid-
neys of vehicle-treated mice (Figures 5(e) and 5(f), resp.). In
agreement with these results, immunohistochemistry studies
revealed reduced amount of fibronectin (Figures 3(a), 3(b),
3(e) and 3(f)) and interstitial 𝛼-SMA (Figures 4(a), 4(b), 4(e)
and 4(f)) in the O kidneys of atorvastatin-treated mice than
in the O kidneys of vehicle-treated animals.
Pull-down and Western blot analysis showed that O
kidneys of FTI-treated mice presented significantly lower
Ras activation than kidneys of vehicle-treated animals
(Figure 6(a)). Administration of FTI significantly blunted the
obstruction-induced increase in pERK1/2 when compared to
control vehicle group, with lower levels of activated protein
also found in NO kidneys of FTI (Figure 6(b)). A slight,
nonsignificant decrease in the expression of pAkt and total
Akt was observed in O kidneys from FTI-treated animals
(Figures 6(c) and 6(d), resp.). We observed a marked and
significant reduction in fibronectin levels of O kidneys after
FTI treatment when compared with kidneys of animals
receiving vehicle administration (Figure 6(e)). In agreement
with these results, immunohistochemical analysis revealed
lower fibronectin staining in the renal cortical interstitium
of O kidneys from FTI-treated mice compared with mice
receiving the vehicle (Figures 3(a), 3(b), 3(g) and 3(h)).
Compared with untreated mice, O kidneys of FTI group
showed a mild although nonsignificant reduction in 𝛼-SMA
levels (Figure 6(f)), which correlates with the interstitial
amount detected by Figures 4(a), 4(b), 4(g) and 4(h).
Western blot analysis showed significantly lower pERK1/2
and pAkt levels in O kidneys from mice that received
chaetomellic acid Awith respect to O kidneys of control mice
(Figures 7(a) and 7(b)). Asmeasured byWestern blotting, the
expression of 𝛼-SMA, but not that of fibronectin was signif-
icantly lower in O kidneys of mice treated with chaetomellic
acid compared with O kidneys of mice treated with vehicle
(Figures 7(c) and 7(d), resp.). Immunohistochemistry analy-
sis revealed that in the animals receiving chaetomellic acid,
O kidneys showed lower staining for 𝛼-SMA but not for
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Figure 1: Effect of systemically administrated angiotensin II (Ang II) on Ras signaling pathway. Ras activation was evaluated as Ras GTP by
ELISA (a). Phosphorylated (p)-ERK1/2 and p-Akt protein expression were evaluated as the ratio p/total protein by Western blot ((b) and (c),
resp.). Bars represent the mean ± SEM of the optical density measured in kidney samples of control saline group (Ctrl; 𝑛 = 3) and angiotensin
II-treated animals (Ang II, 0.8mg/kg; 𝑛 = 3–5/per time point). ∗𝑃 < 0.05 versus control group.
fibronectin thanOkidneys fromanimals receiving the vehicle
alone (Figure 8).
4. Discussion
Increased levels of Ang II have been suggested to play a
major role in the progression of renal disease induced by
experimental UUO [3]. Previous studies have demonstrated
that both mRNA and protein levels are increased for renin,
angiotensin converting enzyme activity, and Ang II content
in the obstructed kidney 1 day after UUO [4]. Additionally,
in vivo studies have shown renal Ras activation induced by
infusion of Ang II for 6 days [18].
Having previously demonstrated that Ras signaling path-
way is activated in obstructed kidneys after 3 days of UUO
[22, 23, 37], we now demonstrate that systemic Ang II
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Figure 2: Effect of losartan administration on UUO-induced Ras pathway activation and fibrotic changes analyzed by Western blot. Protein
expression of Ras (a), ERK1/2 (b), Akt ((c) and (d)), fibronectin (e), and 𝛼-SMA (f) detected by immunoblotting. Activation of Ras and
ERK1/2 were measured as the ratio phosphorylated (p)/total proteins. Bars represent the mean ± SEM of the optical density measured in
nonobstructed (NO) and obstructed (O) kidney samples of saline (𝑛 = 3) and losartan- (Los 40mg/kg; 𝑛 = 5) treated animals. §𝑃 < 0.05
and ∗𝑍 > 2.6383 versus NO vehicle-treated kidneys of UUO mice.
administration in normal mice results in a marked increase
of the renal Ras signaling pathway as early as 30minutes, with
larger increases observed 4 hours after administration. Thus,
our data demonstrates a rapid activation of the Ras pathway
induced by UUO or Ang II administration. Furthermore,
by blocking the AT1 receptor by losartan administration,
levels of activated Ras in obstructed kidneys were markedly
reduced. Taken together, these results suggest that Ang II
leads to AT1 receptor dependent stimulation of Ras in early
renal injury post-UUO.
Fibronectin is a major component of the pathological
extracellular matrix (ECM) in tubulointerstitial fibrosis that
6 BioMed Research International
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Figure 3: Effect of losartan, atorvastatin, or farnesyl transferase inhibitor (FTI) administration on renal fibronectin expression detected by
immunohistochemistry in UUO mice. Representative interstitial sections from nonobstructed (NO) and obstructed (O) kidneys of UUO
untreated control mice ((a) and (b)) and UUOmice treated with losartan ((c) and (d)), atorvastatin ((e) and (f)), or FTI ((g) and (h)). Black
bar indicates 100 microns in all panels.
serves as a fibroblast chemoattractant and scaffold protein for
the deposition of other ECM proteins [38]. Furthermore, the
fibronectin scaffold has been demonstrated to be involved in
the differentiation of fibroblasts to the 𝛼-SMApositivemyofi-
broblasts [39], a key step in UUO-induced renal fibrosis [16].
Since inhibition of UUO-induced Ras activation by losartan
treatment attenuates increases in fibronectin and 𝛼-SMA
expression in the obstructed kidney, a potential role for Ras
beyondmere association could be suggested in relation to the
early stages of Ang II-mediated renal fibrosis.
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Figure 4: Effect of losartan, atorvastatin, or farnesyl transferase inhibitor (FTI) administration on renal alpha-smoothmuscle actin (𝛼-SMA)
expression detected by immunohistochemistry in UUO mice. Representative interstitial sections from nonobstructed (NO) and obstructed
(O) kidneys of UUO untreated control mice ((a) and (b)) and UUOmice treated with losartan ((c) and (d)), atorvastatin ((e) and (f)) or FTI
((g) and (h)). Black bar indicates 100 microns in all panels.
Considering all this data, it could be suggested that in the
early stages of UUO the profibrotic effects of AT1 receptor-
mediated Ang II are regulated, at least in part, via a Ras-
dependent pathway.
Both downstream effectors of Ras, ERK1/2, and Akt
have been implicated in renal damage response in obstruc-
tive nephropathy. We have previously reported that acti-
vation of Ras and ERK1/2 is significantly higher in the
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Figure 5: Effect of atorvastatin administration on UUO-induced Ras pathway activation and fibrotic changes analyzed by Western blot.
Protein expression of Ras (a), ERK1/2 (b), Akt ((c) and (d)), fibronectin (e), and alpha-smooth muscle actin (𝛼-SMA) (f) was detected by
immunoblotting. Activation of Ras and ERK1/2 was measured as the ratio phosphorylated/total proteins. Bars represent the mean ± SEM of
the optical density measured in nonobstructed (NO) and obstructed (O) kidney samples of vehicle (𝑛 = 3) and atorvastatin-treated animals
(Atorv, 70mg/kg; 𝑛 = 4). §𝑃 < 0.05 and ∗𝑍 > 1.9600 versus NO vehicle-treated kidneys of UUO mice. #𝑃 < 0.05 versus O vehicle-treated
kidneys.
obstructed (O) kidneys than in nonobstructed (NO) kid-
neys 3 days after UUO. The same pattern was observed
in UUO-induced expression of p-Akt and total Akt, as
demonstrated by Western and Northern blot analysis [22,
23]. Activation of ERK1/2 has been related to interstitial
apoptosis and proliferation of tubular cells [23, 40, 41],
whereas a role for activated Akt has been reported in early
tubulointerstitial cell proliferation and profibrotic events in
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Figure 6: Effect of farnesyl transferase inhibitor (FTI) administration onUUO-induced Ras pathway activation and fibrotic changes analyzed
by Western blot. Protein expression of Ras (a), ERK1/2 (b), Akt ((c) and (d)), fibronectin (e), and alpha-smooth muscle actin (𝛼-SMA) (f)
was detected by immunoblotting. Activation of Ras and ERK1/2 was measured as the ratio phosphorylated/total proteins. Bars represent the
mean ± SEM of the optical density measured in nonobstructed (NO) and obstructed (O) kidney samples of vehicle (𝑛 = 3) and FTI-treated
animals (40mg/kg; 𝑛 = 5). §𝑃 < 0.05 and ∗𝑍 > 2.6383 versus NO vehicle-treated kidneys of UUOmice. #𝑃 < 0.05 versus O vehicle-treated
kidneys.
UUO [23]. Results presented in this study have also shown
that inhibition of Ras activation by blocking either the
farnesyl transferase or HMG-CoA reductase enzymes is able
to reduce UUO-induced MAPK-ERK1/2 signaling pathway
in the obstructed kidney. Additionally, administration of
atorvastatin or chaetomellic acid A also induced a marked
downregulation of PI3 K/Akt pathway.Thus, blockade of Ras
activation can provide a new strategy to reduce the renal
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Figure 7: Effect of chaetomellic acid A administration on UUO-induced Ras pathway activation and fibrotic changes analyzed by Western
blot. Protein expression of pERK1/2 and ERK1/2 (a), pAkt and Akt (b), alpha-smooth muscle actin (𝛼-SMA) (c), and fibronectin (d) was
detected by immunoblotting. Bars represent the mean ± SEM of the optical density measured in nonobstructed (NO) and obstructed (O)
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kidneys of UUO mice. #𝑃 < 0.01 versus O vehicle-treated kidneys. &𝑃 < 0.01 versus NO Chaet-treated kidney.
damage events elicited by activation of ERK1/2 and Akt
signaling pathways.
Moreover, our data demonstrate that inhibition of Ras
activation by atorvastatin or FTI administration reduces
UUO-induced accumulation of fibronectin in the mouse
kidney. Atorvastatin data are in agreement with previous
studies reporting protective effect of statins in UUO-induced
renal fibrosis [42–46].
In addition, atorvastatin, and chaetomellic acid A
reduced the increased amount of the marker for myofibrob-
lasts, 𝛼-SMA, after UUO. At least a part of myofibroblast
present in the kidney after UUO may derive from epithelial
cells by a process called epithelial-mesenchymal transition
(EMT) [16] and there are enough evidences that Ras acti-
vation participates in EMT [47, 48]. These results suggest
that Ras participates in the initiating molecular events are
involved in renal interstitial fibrogenesis induced by ureteral
obstruction in mice. We have already reported that H-Ras
isoform is able to modulate renal fibrosis and myofibroblast
activation following ureteral obstruction in mice [24, 27].
Notably Ras activation has been shown to be involved in EMT
of tubular cells to myofibroblasts [49], and specifically H-
Ras is involved in TGF-𝛽1-induced EMT [50]. In the kidney,
chaetomellic acid A selectively inhibits themembrane-bound
of H-Ras without affecting the membrane-bound of Ki-
Ras or other prenylated intracellular proteins like Rab [51].
Since H-Ras isoform only can be farnesylated, we have used
chaetomellic acid A specifically to inhibit the activation of H-
Ras isoform.Our results have demonstrated that chaetomellic
acid A administration decreased Ras downstream signaling
pathway as well as 𝛼-SMA accumulation in UUO kidneys.
Previous studies of our group have shown that H-Ras KO
mice show reduced numbers of myofibroblasts in the kidney
following UUO [27]. It has been reported that in acute
renal ischemia-reperfusion injury in rats the inhibition of the
Ras pathway by chaetomellic acid A resulted in a beneficial
effect, preserving both renal function and structure [51].
Furthermore, in an experimental murine model of ischemic
stroke, chaetomellic acid A administration increased the
intracellular concentration of inactive H-Ras, leading to
a marked decrease of both superoxide anion production
and volume of cerebral necrotic tissue, with the subsequent
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Figure 8: Effect of chaetomellic acid A administration on renal alpha-smooth muscle actin (𝛼-SMA) ((a)–(d)) and fibronectin ((e)–(h))
expression detected by immunohistochemistry in UUO mice. Representative cortical interstitial sections from nonobstructed (NO) and
obstructed (O) kidneys of UUOmice treated with vehicle (Control) or chaetomellic acid A (Chaet Acid). Black bar indicates 100 microns in
all panels.
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improved survival of hypoxic neuronal cells [35]. Thus,
inhibition of H-Ras isoform specifically by chaetomellic acid
A could be used as a potential therapeutic strategy to reduce
fibrosis development.
5. Conclusions
In summary, our results suggest that increased Ang II
production in the obstructed kidney could play a role in
Ras/ERK/Akt pathway activation, which in turn, can be
involved in early renal fibrosis induced by UUO. Our data
also offer evidence of the pharmacological potential of Ras
pathway inhibition in preventing the progression of renal
tubulo-interstitial fibrosis. Chaetomellic acid A is of partic-
ular interest in this regard in relation to the arrest or reversal
of renal fibrosis as it acts more specifically than statins and is
less toxic than synthetic FTIs.
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